Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
- Author(s)
- Dreyling, M; Fowler, NH; Dickinson, M; Martinez-Lopez, J; Kolstad, A; Butler, J; Ghosh, M; Popplewell, L; Chavez, JC; Bachy, E; Kato, K; Harigae, H; Kersten, MJ; Andreadis, C; Riedell, PA; Ho, PJ; Pérez-Simón, JA; Chen, AI; Nastoupil, LJ; von Tresckow, B; María Ferreri, AJ; Teshima, T; Patten, PEM; McGuirk, JP; Petzer, AL; Offner, F; Viardot, A; Zinzani, PL; Malladi, R; Paule, I; Zia, A; Awasthi, R; Han, X; Germano, D; O'Donovan, D; Ramos, R; Maier, HJ; Masood, A; Thieblemont, C; Schuster, SJ;
- Details
- Publication Year 2024-04-25,Volume 143,Issue #17,Page 1713-1725
- Journal Title
- Blood
- Publication Type
- Research article
- Abstract
- Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial reported high response rates and excellent safety profile in patients with extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after median follow-up of 29 months (interquartile range, 22.2-37.7). As of 29 March 2022, 97 patients with r/r FL (grades 1-3A) received tisagenlecleucel infusion (0.6 × 108-6 × 108 chimeric antigen receptor-positive viable T cells). Bridging chemotherapy was allowed. Baseline clinical factors, tumor microenvironment, blood soluble factors, and circulating blood cells were correlated with clinical response. Cellular kinetics were assessed by quantitative polymerase chain reaction. Median progression-free survival (PFS), duration of response (DOR), and overall survival (OS) were not reached. Estimated 24-month PFS, DOR, and OS rates in all patients were 57.4% (95% confidence interval [CI], 46.2-67), 66.4% (95% CI, 54.3-76), and 87.7% (95% CI, 78.3-93.2), respectively. Complete response rate and overall response rate were 68.1% (95% CI, 57.7-77.3) and 86.2% (95% CI, 77.5-92.4), respectively. No new safety signals or treatment-related deaths were reported. Low levels of tumor-infiltrating LAG3+CD3+ exhausted T cells and higher baseline levels of naïve CD8+ T cells were associated with improved outcomes. Tisagenlecleucel continued to demonstrate highly durable efficacy and a favorable safety profile in this extended follow-up of 29 months in patients with r/r FL enrolled in ELARA. This trial was registered at www.clinicaltrials.gov as #NCT03568461.
- Publisher
- American Society of Hematology
- Keywords
- Humans; *Lymphoma, Follicular/drug therapy/mortality; Middle Aged; Male; Female; Aged; Adult; Immunotherapy, Adoptive/adverse effects/methods; Neoplasm Recurrence, Local/drug therapy; Receptors, Antigen, T-Cell/therapeutic use; Follow-Up Studies; Treatment Outcome
- Department(s)
- Clinical Haematology
- Publisher's Version
- https://doi.org/10.1182/blood.2023021567
- Open Access at Publisher's Site
https://doi.org/10.1182/blood.2023021567- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-07-04 04:51:22
Last Modified: 2024-07-04 04:51:28